Provided by Tiger Trade Technology Pte. Ltd.

Credit Suisse Holdings

2,490.21
+20.400.83%
Number of Gainers:64
Number of Losers:31
Number of Flat:2
PE:- -
High:2,497.97
Open:2,469.80
Low:2,469.80
Close:2,469.81
Volume:1.28B
Turnover:276.31B
Market Cap:52.14T
Float Cap:48.78T

Loading ...

BlackRock to Report Third-Quarter 2026 Earnings Before NYSE Open

Reuters
·
Sep 30

BlackRock to Report Third Quarter 2026 Earnings on October 14TH

THOMSON REUTERS
·
Sep 30

McDonald’s Stock Forecast: AI Pricing and $8.5 Billion Plan Test MCD’s Recovery

TradingKey
·
Sep 30

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Market Chatter: FTC to Open Probe Into Anthropic, OpenAI Over Consumer Risks

MT Newswires Live
·
Sep 30

National Real Estate Advisors Promotes Ben Kanne to Managing Director, Investments

Reuters
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Tesla Consensus Sees Q3 2026 Total Deliveries at 461,974 Vehicles

Reuters
·
Sep 30

Nasdaq Extends Gains to 1%, S&P 500 Currently Up 0.58%

Deep News
·
Sep 30

Option traders moderately bearish in Moderna with shares down 6.7%

TIPRANKS
·
Sep 30

Anthropic's Potential $2 Trillion-Plus IPO Supports Robust AI Infrastructure Spending, Wedbush Says

MT Newswires Live
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Amazon call volume above normal and directionally bullish

TIPRANKS
·
Sep 30

Morgan Stanley Currently Down Seven Consecutive Days, on Track for Longest Losing Streak Since January 2024

Dow Jones
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30